Shockwave Medical Inc   (SWAV)
Other Ticker:  
Price: $182.2000 $7.65 4.383%
Day's High: $183.21 Week Perf: 6.93 %
Day's Low: $ 171.67 30 Day Perf: -14.68 %
Volume (M): 714 52 Wk High: $ 315.95
Volume (M$): $ 130,145 52 Wk Avg: $227.00
Open: $174.03 52 Wk Low: $157.00

 Market Capitalization (Millions $) 6,959
 Shares Outstanding (Millions) 38
 Employees 300
 Revenues (TTM) (Millions $) 670
 Net Income (TTM) (Millions $) 244
 Cash Flow (TTM) (Millions $) 370
 Capital Exp. (TTM) (Millions $) 34

Shockwave Medical Inc
Shockwave Medical Inc. is a growing medical technology company based in Santa Clara, California, that aims to transform the way cardiovascular diseases are treated. The company specializes in developing products that employ a unique technology known as intravascular lithotripsy (IVL) to treat coronary and vascular calcified lesions.

Founded in 2009 by Dr. John Adams, the company has been successful in raising capital from well-known venture capitalists such as Norwest Venture Partners, Venrock, and Fidelity Management & Research Company, and has been listed on the NASDAQ under the ticker "SWAV" since March 2019. The company's mission is to develop innovative tools to disintegrate calcified arterial plaque, improving patient outcomes and quality of life.

Shockwave's technology, IVL, is a non-invasive, photoacoustic intravascular ultrasound-guided technique that utilizes sound waves to break down calcifications within arteries. The device uses an ultrasound probe to visualize the calcifications and deliver high-frequency sound waves to break them up into small particles that can be naturally eliminated by the body. This process differs from conventional treatment methods such as rotational atherectomy or laser atherectomy, which use a rotating blade or a laser to grind or vaporize plaque.

Shockwave's flagship device is the Shockwave Intravascular Lithotripsy System, which has received regulatory approval in the USA, Europe, and Japan. The device is approved for use in the treatment of severe coronary artery disease (CAD) and peripheral artery disease (PAD) in the lower legs. The Shockwave System has several benefits over conventional approaches to treating calcified lesions, including the ability to treat longer, more complex lesions with less injury to the artery walls and an improved safety profile due to a lower risk of perforation.

The company has amassed positive clinical trial data, including the DISRUPT PAD study, which demonstrated that the Shockwave System improved blood flow in more than 80% of patients with calcified PAD and that the benefits persisted at 12-month follow-up. Additionally, the DISRUPT CAD study suggested IVL was safe and effective in patients with calcified coronary lesions, with a low rate of procedural complications.

In recent years, the company has expanded its product pipeline, including the recent launch of the Shockwave S4 catheter, a next-generation version of the Shockwave Lithoplasty System. The company's sales have been increasing rapidly, and it continues to expand its geographical presence worldwide, with an increasing number of clinicians recognizing the benefits of the Shockwave System.

Overall, Shockwave Medical has established itself as a foremost leader in the field of cardiovascular disease treatment, with an innovative technology and a product portfolio that are poised to have significant impact on the treatment of patients with cardiovascular calcifications.

   Company Address: 5403 Betsy Ross Drive Santa Clara 95054 CA
   Company Phone Number: 279-4262   Stock Exchange / Ticker: NASDAQ SWAV
   SWAV is expected to report next financial results on February 26, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Aurora Technology Acquisition Corp

ATAK, contraction in the operating behavior throughout the July to September 30 2023 period

While the earnings season of the July to September 30 2023 continues, many businesses have reported the earnings. Among them, have been many corporations in the Medical Equipment and Supplies industry. And now, ATAK issued operating deficit of $-0.4793 million, for the third quarter of 2023 earnings season.

Vivos Therapeutics Inc

Vivos Therapeutics Inc. Defies Financial Odds in the Demanding Times of September 2023

For the fiscal time-frame closing September 30 2023 Vivos Therapeutics Inc decreased a loss per share of $-1.75 per share compare to $-6.50 a year before and Income per Share improved from $-4.50 per share from the preceding reporting season. The revenue crumbled by -31.748 % to $2.90 million from $4.25 million in the corresponding reporting season a year before and sequentially Revenue decreased by -6.456 % from $3.10 million.

Vystar Corporation

Devastating Blow: Medical Equipment and Supplies Company Suffers Major Setback in Q3 2023 Financial Report

For the financial interval ending September 30 2023 Vystar Corporation decreased a loss per share of $-0.03 per share compare to $-0.23 a year prior and Income per Share improved from $-0.04 per share from the previous reporting season. The revenue went down sharply by -98.311 % to $0.06 million from $3.57 million in the comparable reporting season a year prior and sequentially revenue surged by 67.054 % from $0.04 million. The remainder ofMedical Equipment and Supplies sector, posted a revenue improvement in the third quarter of 2023.

Petvivo Holdings Inc

Petvivo Holdings Inc Experiences Widening Losses in Q2 2024 Amid Decrease in Orders

As an investor closely following Petvivo Holdings Inc, the recent financial results have presented a mixed bag of challenges and opportunities. In the second quarter of 2024, the company experienced lower turnover, resulting in a significant revenue decrease and a larger shortfall per share compared to the previous year. However, there were notable signs of potential growth and increasing demand within the Medical Equipment and Supplies industry.
One of the key financial indicators is the revenue, which decreased by -7.127% to $0.21 million year on year. This decline is concerning for Petvivo Holdings Inc, as it points to potential shortcomings in the company's ability to generate sales. Comparatively, the Medical Equipment and Supplies industry as a whole recorded a top-line rise in the same period, suggesting that Petvivo may be facing certain internal challenges.

Ir Med Inc

Ir Med Inc announced operating profit of $1.197 million, in the third quarter of 2023 financial report

As an observer of the Medical Equipment and Supplies sector, I have thoroughly analyzed the third quarter financial results of Ir Med Inc. The company's performance took center stage in this report, overshadowing the same period in the previous year. Despite operating predominantly in the development phase, Ir Med Inc showcased a bullish quarter, signaling potential growth prospects.
Notably, Ir Med Inc reported an operating profit of $1.197 million for the July to September 30, 2023 quarter, without any reported revenue. This indicates that the company is focusing on developing its services rather than generating immediate revenue. Such a strategic course of action is crucial for a business aiming to establish a strong foundation before entering the market.


Shockwave Medical Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com